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Abstract
Background: Due to our aging population, an increase in proximal femur fractures can be expected, which is
associated with impaired activities of daily living and a high risk of mortality. These patients are also at a high risk
to suffer a secondary osteoporosis-related fracture on the contralateral hip. In this context, growth factors could
open the field for regenerative approaches, as it is known that, i.e., the growth factor BMP-7 (bone morphogenetic
protein 7) is a potent stimulator of osteogenesis. Local prophylactic augmentation of the proximal femur with a
BMP-7 loaded thermoresponsive hydrogel during index surgery of an osteoporotic fracture could be suitable to
reduce the risk of further osteoporosis-associated secondary fractures. The present study therefore aims to test the
hypothesis if a BMP-7 augmented hydrogel is an applicable carrier for the augmentation of non-fractured proximal
femurs. Furthermore, it needs to be shown that the minimally invasive injection of a hydrogel into the mouse
femur is technically feasible.
Methods: In this study, male C57BL/6 mice (n = 36) received a unilateral femoral intramedullary injection of either
100 μl saline, 100 μl 1,4 Butan-Diisocyanat (BDI)-hydrogel, or 100 μl hydrogel loaded with 1 μg of bone morphogenetic
protein 7. Mice were sacrificed 4 and 12weeks later. The femora were submitted to high-resolution X-ray tomography
and subsequent histological examination.
Results: Analysis of normalized CtBMD (Cortical bone mineral density) as obtained by X-ray micro-computed
tomography analysis revealed significant differences depending on the duration of treatment (4 vs 12 weeks; p < 0.05).
Furthermore, within different anatomically defined regions of interest, significant associations between normalized TbN
(trabecular number) and BV/TV (percent bone volume) were noted. Histology indicated no signs of inflammation and
no signs of necrosis and there were no cartilage damages, no new bone formations, or new cartilage tissues, while
BMP-7 was readily detectable in all of the samples.
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Conclusions: In conclusion, the murine femoral intramedullary injection model appears to be feasible and worth to
be used in subsequent studies that are directed to examine the therapeutic potential of BMP-7 loaded BDI-hydrogel.
Although we were unable to detect any significant osseous effects arising from the mode or duration of treatment in
the present trial, the effect of different concentrations and duration of treatment in an osteoporotic model appears of
interest for further experiments to reach translation into clinic and open new strategies of growth factor-mediated
augmentation.
Keywords: Osteoporosis, Murine femoral intramedullary injection model, Bone morphogenetic protein 7 (BMP-7),
BDI-hydrogel
Background
In older adults, osteoporosis is the most common dis-
ease of the bone and will acquire increasing importance
due to the demographic changes of our aging population
[1]. Up to 27% of patients with a diagnosed osteoporosis
already sustained a fracture [2]. Without any medica-
mentous therapy, patients with multiple osteoporosis-as-
sociated fractures will sustain in up to 85% another
fracture [2]. The proximal femur fracture is one of the
most common osteoporosis-associated fractures and
often the consequence of an untreated osteoporosis [3].
It is known that for patients with an osteoporosis-associ-
ated femoral fracture the risk of sustaining a secondary
fracture of the contralateral side is between 2.3 and
10.6% [4, 5]. Mortality of patients with a secondary
femoral fracture during the first year after fracture is sig-
nificantly increased compared to unilateral femoral frac-
tures and ranges from 8.4 to 36% [5]. Sawahla et al.
described that in two thirds of patients with secondary
femoral fracture, the second fracture was at the corre-
sponding anatomical location and that approximately
70% of second fractures occurred within 3 years [6].
Therefore, approaches for prophylaxis of secondary
fractures should have the aim to counteract these devel-
opments. Current prevention measures aim at a strict
compliance of the patients concerning medicamentous
and non-medicamentous therapies, which is often diffi-
cult because of comorbidities such as cognitive disorders
or dementia [7]. Local osteo-enhancement procedures as
mentioned in the new “European guidance for the diag-
nosis and management of osteoporosis in postmeno-
pausal women” could offer an alternative treatment for
this problem [8]. These procedures comprise a minimal-
invasive injection of a resorbable synthetic bone graft
substitute, containing a proprietary triphasic calcium
sulphate/calcium phosphate implant in the femoral neck,
which leads to an increase of femoral BMD (bone min-
eral density) [8].
Strengthening the femoral neck with a thermosensitive,
biocompatible material such as a hydrogel loaded with the
growth factor BMP-7 could provide another opportunity.
Hydrogels are intensively investigated as carriers for
biologicals in the context of tissue engineering [9, 10]. A
wide used material on which many hydrogels are based
on is Pluronic. Pluronic is a thermosensitive polymer,
which is gelling when exceeding a critical solution
temperature (LCST) [11, 12]. Furthermore, different
chain extenders can modify Pluronic and its chemical
properties. In this study, a Pluronic (P123)-based hydro-
gel (Europe Patent number: WO2014095915A1) was
used, which was extended by butane diisocyanate (BDI)
to have the desired properties, e.g., thermosensitivity. As
shown in previous experiments by some of the authors,
1,4-butane diisocyanate extended triblock copolymer
Pluronic P 123 (BDI-hydrogel) gels at body temperature
and offers good biocompatibility and improved cell sur-
vival under in vitro and in vivo circumstances [12]. Its
bioresorbable characteristics further provide an effective
carrier for the subsequent release of growth factors.
BMPs are clinically used because of their potent
osteoinductive stimulation [13]. This stimulation of bone
formation becomes especially relevant under certain
conditions, e.g., osteoporosis and fracture healing [14,
15]. BMP-7 gained approval for local treatment of dis-
tinct bone-related conditions, e.g., posterolateral spinal
lumbar fusion and complicated permanent tibial pseu-
darthrosis [9, 10]. However, utilization of BMP-7 as a
therapeutic drug poses a variety of problems. On the
one hand, application has to be restricted to the desired
site of action in order to avoid ectopic mineralization,
and on the other hand biological half-life is in the range
of a few minutes only [16]. Thus, either repeated appli-
cations are required or the BMP-7 has to be trapped in-
side a biodegradable matrix with subsequent slow and
long-lasting release of the bioactive growth factor at the
predefined site of action [17].
The present study therefore aims to test the hypoth-
esis if a BMP-7 augmented hydrogel is an applicable
carrier for the augmentation of non-fractured proximal
femurs. To test this hypothesis, the murine femoral
intramedullary injection model was used in the present
pilot study (proof of principle) to gain knowledge on
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the biocompatibility and features of a BMP-7-loaded
BDI-hydrogel in vivo.
Methods
Preparation of butane-diisocyanate hydrogel (BDI-hydrogel)
The synthesis of the BDI extended, thermoresponsive
Pluronic 123 polymer has been previously described by
Volkmer et al. [12]. For preparation of the hydrogel, 1 g of
autoclaved polymer was dissolved under aseptic condi-
tions in 9ml of minimum essential medium alpha with L-
glutamin (MEMalpha; Invitrogen, USA) supplemented
with 10% fetal bovine serum (FBS; Sigma, Germany) and
40 IU/ml penicillin/streptomycin (PAA Laboratories
GmbH, Austria), stored at 4 °C and gently stirred once per
day [12]. At the day of surgery, rhBMP-7 (Olympus Bio-
tech Corporation, Mt Waverley, Victoria, Australia) was
added to yield a final concentration of 100 μg/ml rhBMP-
7, and the solution was stored on ice until application.
Animals and surgical procedure
Thirty-six male C57BL/6 mice were delivered at 6
months of age from Charles River Laboratories, Inc.
(Sulzfeld, Germany), and all animals had access to main-
tenance diet and water ad libitum. Mice were kept in in-
dividually ventilated standard cages (6 mice per cage) in
a temperature-controlled room on a 12-h light/dark
cycle. After 2 weeks of acclimatization, mice were ran-
domly allocated to three experimental groups, i.e., fem-
oral intramedullary injection of either 100 μl saline
(Sham group, n = 12), 100 μl BDI-hydrogel (Hydrogel
group, n = 12), or 100 μl BMP-7 loaded BDI-hydrogel
(BMP-7 group, n = 12) with scheduled observation pe-
riods of 4 and 12 weeks. Surgery was done at the right
hindlimb in all animals. Anesthesia was achieved by in-
traperitoneal injection of fentanyl (0.05 mg/kg body
weight (BW)), midazolam (5mg/kg BW), and medetomi-
dine (0.5 mg/kg BW). Surgery was performed as de-
scribed by Zilber et al. except utilization of a dental drill
to get access to the intramedullary cavity [18]. Thus, sur-
gical approach was provided via a 5-mm anterolateral
skin incision to expose the patellar tendon. Via blunt
dissection of the tendon surrounding tissue and joint
capsule, the distal aspect of the femoral shaft was then
exposed. The intramedullary space was cannulated with
a 29G needle and the compounds mentioned above were
delivered to the proximal femur by means of a syringe.
The incision was closed using a 4-0 Ethilon skin suture
(Ethicon, Sommerville, NJ, USA), and anesthesia was an-
tagonized with naloxon (1.2 mg/kg BW), flumazenil (0.5
mg/kg BW), and atipamezol (2.5 mg/kg BW) dissolved
in 0.9% saline, each. Animals were placed under a red
light until fully awake.
At the end of the scheduled observation period, animals
were sacrificed in a CO2 chamber. Both hindlimbs were
extracted; the femora were freed from muscle and
adjacent tissue and immediately fixed in 10% formalin for
24 h. Thereafter, bones were incubated in 70% ethanol
(24 h) and stored in 80% ethanol until further analysis.
High-resolution three-dimensional X-ray tomography
(μCT) of the femora
A high-resolution μCT-imaging system (Skyscan 1076,
Bruker, Kontich, Belgium) was utilized essentially as de-
scribed [19]. Briefly, femora were rinsed with distilled
water twice, equilibrated with 0.9% NaCl (4 °C over-
night), and wrapped in cling film, and up to three bones
were placed sequentially into cylindrical polypropylene
tubes. The tubes were held by means of a Styrofoam
bedding with the long axis of the bones orientated or-
thogonally to the X-ray beam. The instrumental settings
chosen for scanning, reconstruction (NRecon, Bruker),
and image analysis (CTAn, Bruker) are given in Table 1.
Distinct volumes of interest (VOI) for analysis of cortical
(cort) and trabecular (trab) bone were defined relative to
anatomical landmarks (Fig. 1). In particular, cortical and
trabecular bone were investigated at the diaphysis (cort),
the distal femur (trab), the proximal metaphysis (cort,
trab), and femoral neck (cort, trab), respectively. For
analysis of cortical bone, a manually drawn bagel-like re-
gion of interest (ROI) was defined whereas manually
drawn polygonal ROIs were used for analysis of trabecu-
lar bone. Size and shape of the polygonal ROIs were
adjusted manually every 10–30 transverse slices and ad-
justed automatically by the software over the entire VOI
(Fig. 1). All ROI interpolations were checked visually
Table 1 Setting of the μCT for scanning, reconstruction, and
analysis of bone microarchitecture
Settings for
Recording of 3D images
X-ray 48 kV/200 μA
Filter 0.5 mm Al
Pixel size 9 μm




Defect pixel masking 20%
Beam hardening 30%
Misalingment compensation calculated individually
Analysis
Tresholding of gray values
Cortical bone 100 - 255
Trabecular bone 85 - 255
Removal of white speckles < 30 voxel
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before starting the CTAnalyzer software. Parameters
used for the characterization of cortical and trabecular
bone are given in Table 2 [20]. For calculation of bone
mineral density, calcium-hydroxyapatite (CaHA) phan-
tom rods containing 0.25 and 0.75 g CaHA/cm3 were
used for calibration of the instrument [19].
Preparation of bone samples for histological and
immunohistochemical analysis
Methyl methacrylate embedding of mineralized bone
Per group, two pairs of randomly selected femora were
embedded in methyl methacrylate (MMA, Technovit
9100 Heraeus-Kulzer, Wehrheim, Germany) and subse-
quently used for immunohistochemical evaluation. Em-
bedding in MMA and preparation of the required
solutions were according to the protocol of the manufac-
turer except that the procedure was performed manually
[21]. Briefly, intact femora were dehydrated with increas-
ing amounts of ethanol (70%, 80%, 90%, 96%, each for
24 h at 4 °C followed by two incubations in 100% ethanol
(each 12 h at 4 °C) and defatting with xylene (2 × 12 h at
4 °C). Subsequently, the tissue was sequentially soaked
with a 1:1 mixture of monomer and xylene (24 h at 4°),
with monomer containing hardener 1 at a concentration
of 3.4 mg/ml (24 h at 4 °C), with destabilized monomer
containing 0.08 g/ml of polymethylmethacrylate
(PMMA) and 4mg/ml of hardener 1 (3–5 days at 4 °C).
Finally, each sample was placed in a labeled Teflon-made
polymerization mold and covered completely with
polymerization solution (approx. 2 ml per sample), i.e.,
10 volumes of destabilized monomer containing PMMA
(0.16 g/ml) and hardener 1 (10mg/ml) were mixed with 1
volume of destabilized monomer containing 0.08ml/ml
hardener 2 and 0.04ml/ml regulator immediately before
use. To ensure optimal conditions for polymerization, a
mild vacuum was applied prior to closing the molds. Sub-
sequently, the samples were stored at − 7 °C until






Fig. 1 Schematic representation of the VOIs selected for analysis of cortical and trabecular bone microarchitecture (a), the distal growth plate as
an example of an anatomical landmark (b), representative images of the manually drawn ROIs for analysis of cortical (c), and trabecular (d) bone.
The distal growth plate and the division into greater trochanter and femoral neck served as internal references, i.e., positioning of the VOIs for
analysis of the distal and proximal femora as well as the femoral neck. For examination of the distal femur (1), VOI started 50 slices apart from the
growth plate (b) and consisted of 100 slices. The VOI in the region diaphysis (2) started 400 slices apart from the growth plate and consisted of
100 slices. In case of the proximal femur (3), trab and cort VOIs consisted of 80 slices each and started 50 slices distal from the division into greater
trochanter and femoral neck. For analysis of the femoral neck (4), cort VOI and trab VOI included 20 slices each and an offset of 15 slices from the
division into greater trochanter and femoral neck was used
Table 2 Parameters used for the description of cortical and
trabecular bone
Characteristics of cortical bone
BAr/TAr, % bone area / tissue area
CtTh, mm cortical thickness
CtBMD, g/cm3 cortical bone mineral density
Characteristics of trabecular bone
BV/TV, % bone volume fraction
TbN, 1/mm trabecular number
TbTh, mm trabecular thickness
TbSp, mm trabecluar separation
DA degree of aniostropy
TbBMD, g/cm3 trabecular bone mineral density
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were trimmed and pre-cut in the area of interest with a
diamond saw (Buehler Isomet 1000, Esslingen am Neckar,
Germany). The surface of the blocks were polished and
mounted on Leica Xtra adhesive slides with a special
cyanacrylic glue (LLS ROWIAK LaserLabSolutions,
Hannover, Germany). Ten-micrometer sections were
prepared with a laser microtome (TissueSurgeon, LLS
ROWIAK LaserLabSolutions, Hannover, Germany).
Immunohistochemistry
For immunohistochemical analysis of mineralized bone,
sections were deplasted with methylmethacrylate (24 h)
followed by overnight incubation with Shandon xylene
substitute (Fisher Scientific, Schwerte, Germany). Subse-
quently, the slides were rinsed with distilled water,
incubated in 2M HCl (1 h, 37 °C), rinsed again with dis-
tilled water and 0.1M Tris-HCl (pH 3.7) prior to trypsi-
nization (0.5 mg/ml in 1% CaCl2; 30 min, 37 °C) for
antigen demasking. Afterwards, the slides were rinsed
with 0.1 M Tris-HCl and endogeneous peroxidase was
blocked by incubation with 10% H2O2 (30 min, room
temperature). For blocking of unspecific binding sites
and visualization of bound antibody, the Vectastain Kit
Elite Universal (Vector Laboratories Inc., Burlingame,
CA, USA) was used according to the instructions of the
manufacturer and essentially as described previously
[22]. For detection of BMP-7, slides were incubated (4°,
overnight) with the protein-A purified polyclonal rabbit-
anti-BMP-7 antiserum (ab#56023, Abcam, Cambridge,
UK), which was diluted with blocking serum to reach a
concentration of 5 μg/ml. Paraffin-embedded samples
from healthy human kidney served as controls.
Paraffin embedding and histochemical analysis of
demineralized bone
Per group, two randomly selected pairs of femora were
decalcified manually (Usedecalc®, Medite, Burgdorf
Germany) at 4 °C for a total of 2 weeks with daily changes
of the decalcification solution. Finally, the samples were
washed with deionized water, dehydrated, cleared, and
embedded in paraffin. Tissue samples (5-μm sagittal sec-
tions mounted on Superfrost® slides) were prepared for
Masson-Goldner trichrome staining essentially as de-
scribed previously [22, 23].
Statistical analysis
All data were processed using IBM SPSS Advanced Sta-
tistics 22.0. Values are expressed as mean ± standard de-
viation (SD) for the indicated number of samples. For
each animal, an individual left-to-right normalization of
the measurements obtained from femora was performed
for quantitative analysis of bone microarchitecture.
Parameters describing trabecular and cortical bone
(Table 2) were analyzed and compared with repeated
measure ANOVA for factors “treatment” (i.e., sham, BDI-
hydrogel, and BMP-7) and “duration” (i.e., 4 or 12 weeks)
with post hoc least significant difference (LSD) test, as well
as for the within-subjects factor “localization” (i.e., diaph-
ysis (cort), distal femur (trab), proximal femur, and
femoral neck) with deviation-contrast, employing a gen-
eral linear model for repeated measures (GLM-Rep), if
normality was given. Here, estimated marginal means
(EMMs) with their standard errors (SEEMM) and the re-
spective 95% confidence intervals (CIs) are reported.
Spearman Rho (R) test was used to analyze the correlation
between normalized parameters describing trabecular and
cortical bone, respectively.
In case of non-normality, nonparametric analysis of
variance was performed employing the Kruskal-Wallis
test for unpaired samples and the Friedman test for
paired data, respectively. If appropriate, subgroups were
tested pairwise using the Mann-Whitney U test (un-
paired samples) or the Wilcoxon signed rank sum test
(paired data), two-sided.
Normal distribution of measurements was checked
using the Kolmogorov-Smirnov test. P < 0.05 (Bonfer-




The postoperative course was uneventful; wound healing
was without any complications and no animal had to be
taken out of the experiment before the end of the obser-
vation period.
Analysis of bone microarchitecture
For each mouse, characteristics of cortical and trabecular
microarchitecture were determined at the distal and
proximal femur as well as the femoral neck of both hin-
dlimbs. Normalized data on distinct features of bone
microarchitecture relative to predefined anatomical
landmarks together with data on treatment and duration
are available. In order to investigate intrasubject interac-
tions between these variables, the GLM-Rep model was
applied. The analysis revealed that normalized TbN
(trabecular number), TbTh (trabecular thickness), and
the degree of anisotropy were virtually unrelated to the
region investigated and were even not affected by the
mode or duration of therapy (Additional file 1: Table
S1). By contrast, normalized TbSp (trabecular separ-
ation) at the femoral neck was significantly lower com-
pared to the distal and proximal femur, respectively
(Table 3). While normalized trabecular BMD (bone min-
eral density) determined at the distal femur and femoral
neck were almost comparable, it was significantly lower
at the proximal femur (Table 3). However, neither
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normalized TbSp nor normalized trabecular BMD was
affected by mode or duration of treatment.
Within each of the anatomically defined regions, sig-
nificant associations between normalized TbN and either
normalized BV/TV (percent bone volume) or normal-
ized BMD as well as between normalized BV/TV and
normalized BMD were noted (Fig. 2). Furthermore, nor-
malized BMD determined at the distal and proximal
femur were significantly associated (R = 0.61, p < 0.001).
In case of cortical bone, the normalized BAr/TAr
(bone area/tissue area) at the femoral neck was signifi-
cantly higher compared to those determined either at
the diaphysis or at the proximal femur (Table 3). Again,
there were no effects related to the mode or duration of
treatment. While the normalized CtBMD (Cortical bone
mineral density) was unrelated to the region investigated
or the mode of therapy, the linear model revealed a sig-
nificant effect depending on the duration of treatment (4
vs 12 weeks, 1.001 (0.978, 1.023) vs. 0.988 (0.966, 1.010);
p < 0.05). This effect is even more pronounced when the
effects of localization and mode of treatment are not
considered at all, i.e., the U test revealed p = 0.002. Cor-
relation analysis revealed a positive association between
the normalized CtBMD determined at either anatomical
region (diaphysis and proximal femur, R = 0.75; diaphysis
and femoral neck, R = 0.71; proximal femur and femoral
neck, R = 0.64; each p < 0.001).
Histological analysis and detection of BMP-7
Histological analysis of demineralized paraffin-embedded
bones did not reveal any signs of inflammation, such as
clusters of granulocytes or inflammation foci. Neither,
we could detect differences related to the mode or
duration of the treatments (Fig. 3). No signs of necrosis
could be detected throughout all specimens. Also, there
were no cartilage damages, no new bone formations or
new cartilage tissues.
BMP-7 was readily detectable in all of the samples in-
vestigated (Fig. 4). In particular, there were no differ-
ences regarding the intensity of BMP-7-specific signals
with respect to mode and duration of treatment.
Discussion
Prophylactic augmentation of the proximal femur could
offer an alternative strategy to reduce the high risk of
secondary hip fractures associated with an underlying
osteoporosis. This technique could be applied in non-
fractured proximal femurs of patients undergoing
surgery due to an osteoporosis-related fracture. While
augmentation techniques available at present are based
on either inert materials such as PMMA (Polymethyl-
methacrylate) or calcium-phosphate materials, the use of
growth factor-augmented hydrogels could offer a new
regenerative approach.
In order to evaluate the potential of a BMP-7-aug-
mented hydrogel the present study was designed and con-
ducted as a pilot (proof of concept) and with the vision for
future utilization of a BMP-7-loaded hydrogel for pre-
emptive augmentation of the femoral head in osteoporotic
patients. A thorough investigation of this concept requires
a sequence of well-designed animal experiments, covering
all aspects from the feasibility of the surgical approach
and biocompatibility up to toxicological and finally
pharmacological effects. Our experiment was the first in
this chain of events although no osteoporotic animals
were used in the present in vivo analysis, we can clearly
state that the mice tolerated the minimal-invasive surgical
procedure well including assessment of the intramedullary
cavity by means of a drill and concomitant application of
the compounds. All mice were operated by the same sur-
geon and the postoperative recovery was without any
complications. Neither μCT imaging nor histochemical in-
vestigation revealed any signs of surgically induced bone
defects, inflammatory or reactive bone marrow changes
secondary to the intervention.
Within the femur, we characterized bone microarchi-
tecture by means of μCT imaging at four distinct ana-
tomical regions, i.e. at the distal femur, the diaphysis, the
proximal femur, and the femoral neck, and per mouse
normalized data were generated. It is still a matter of
discussion which part of the femur is best suited to
characterize bone microarchitecture [24]. Furthermore, a
general linear model for repeated measures was used to
account for the factors “treatment” and “duration” as
well as the within-subjects factor “localization”. This ap-
proach revealed that localization is relevant only for
some of the parameters describing cancellous and
Table 3 Normalized TbSp, normalized TbBMD, and normalized
BAr/TAr relative to the investigated part of the femur. Estimated
marginal means (EMM) with their 95% CIs from GLM-Rep model
are reported. Superscripts denote significant differences between
groups labeled identically (*p < 0.05; **, ##p < 0.01)
EMM SEEMM 95% CI
Normalized TbSp
Distal femur 1.049* 0.022 1.003 - 1.095
Proximal femur 1.050** 0.021 1.007 - 1.093
Femoral neck 0.977*,** 0.022 0.933 - 1.022
Normalized TbBMD
Distal femur 0.960** 0.023 0.911 - 1.008
Proximal femur 0.882**,## 0.027 0.825 - 0.938
Femoral neck 1.056## 0.063 0.924 - 1.187
Normalized BAr/TAr
Diaphysis 0.988** 0.018 0.951 - 1.025
Proximal femur 1.028* 0.017 0.992 - 1.064
Femoral neck 1.097**,* 0.031 1.032 - 1.161
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cortical bone, respectively. In particular, BMD was lower
at the proximal femur compared to the femoral neck or
the distal femur, while TbSp was lowest and BAr/TAr was
highest at the femoral neck. Both mineral density and tra-
becular microarchitecture, i.e., the spatial arrangement,
contribute to stability. Results from the correlation ana-
lysis also point to a strong interaction between these two
features. Furthermore, CtBMD decreased with aging.
However, we could not detect increased bone formation
secondary to local BMP-7 application.
In the present study, we applied for the first time (to
the best of our knowledge) 100 μl pure or BMP-7-loaded
BDI-hydrogel into the murine femoral cavity in vivo.
Previous studies have shown that the BMP dosage is of
importance with regards to osteoinduction. Yet, in litera-
ture, there is limited data on the concentration of BMP-
7, whereas more information has been published on the
concentration of BMP-2, which is why the choice of
doses also considered reports on BMP-2 [25]. In the
present study, we selected an amount of 100 μg/ml
rhBMP-7. This concentration appeared reasonable in ac-
cordance to previous investigations in a small-animal
study reported by Bosemark et al. in which a concentra-
tion of 25 μg BMP-7 was used [26]. Furthermore, in
another dose-response study on BMP-7 mediated frac-
ture healing utilizing a rat femoral critical size defect
Fig. 2 Significant association of normalized TbN (a) and normalized BMD (b) with normalized BV/TV determined at the femoral neck (red triangle),
proximal (blue circle) and distal femur (white circle), respectively. Spearman’s rank coefficients of correlation: femoral neck, R = 0.94 (a) and R = 0.79 (b);
proximal femur, R = 0.88 (a) and R = 0.90 (b); distal femur, R = 0.95 (a) and R = 0.88 (b); each p < 0.001






Fig. 3 Hematoxylin-Eosin (HE)-stained sagittal sections of demineralized femora obtained 4 and 12 weeks after surgery. Femora on the right side
were treated with either BMP-7 loaded BDI-hydrogel, intramedullary application of plain BDI hydrogel or saline (SHAM), the left sides serve as
untreated controls. (Scale bar, 100 μm)
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stabilized with a plate, the authors reported that a
concentration of 50 μg was sufficient to induce bone
healing [27].
A clear limitation of the experimental setup is the appli-
cation of hydrogel through the distal femur. Although the
hydrogel was applied as close to the femoral neck as pos-
sible, this does not guarantee that the hypothesized effects
are restricted to the femoral neck. Further experiments by
some of the authors on the properties of the hydrogel used
compared to different hydrogels such as hexamethylene
diisocyanate (HDI) and hydrogenated diphenylmethane
diisocyanate (H12 MDI) showed that the BDI hydrogel as
used in the present case provides the highest penetration
resistance, which is of importance for injection of the bio-
material [12]. Also, previous studies of our group with ca-
daveric mice clearly showed a homogeneous distribution
of the BDI-hydrogel within the femoral cavity (Additional
file 2).
Immunohistochemistry for detection of BMP-7 further
showed that BMP-7 related signals were comparable be-
tween samples and most likely not related to the specific
treatments. These findings are well in line with the data
obtained by μCT imaging. Yet, in order to discriminate
between exogenous and endogenous BMP-7, a tagged
form, e.g., GFP-l or His-tagged rhBMP7 should be used in
the future. Such an approach requires an additional set of
controls and one has to ensure that the label itself does
not interfere with the desired action of the growth factor
and/or the designated analytical procedures.
Contrasting to our expectations, we were unable to de-
tect any change in terms of bone morphology and
mineralization, which suggests that further studies are
necessary towards an optimization of the BMP-7 con-
centration. Previous unpublished in vitro analysis by our
group showed a continuous release of rhBMP-7 from
the gel over a period of 38 days. In light of these in vitro
results, we expected a higher content of BMP-7 in the
BMP-7-treated bones and an osteoinductive effect to be
detected via μCT analysis.
Under physiological conditions, bone formation and
degradation are well-balanced [28, 29]. Thus, one might
not necessarily expect that the local application even of
an extremely potent growth factor like BMP-7 will be
able to overwrite the system of checks and balances in
an otherwise healthy system. Therefore, this approach
might reveal more robust results in a pathological rodent
model, e.g., in a model of osteoporosis. Furthermore, we
cannot rule out that we missed the peak, i.e., that there
was an acute and intermediate effect within the first 1 or
2 weeks after surgery. Thus, for further analysis of this
approach, a mouse model after induction of osteoporosis
by for example orchiectomy or even with manifested dis-
ease appears to be more appropriate and represents the
next logical step. Furthermore, by the time when the ex-
periments were planned and performed, BMP-7 was
provided on the market by Olympus Biotech Corp.,
which later in 2014, discontinued the sale of its prod-
ucts. Considering the recent market development with
BMP-2 still on the market, an investigation of a BMP-2
augmented hydrogel would be desirable. The gel could
also be loaded with other osteoinductive substances, e.g.,
anti-sclerostin antibodies.
Conclusions
Augmentation techniques of the proximal femur could
open the door for alternative strategies to reduce the
high risk of secondary hip fractures associated with an
underlying osteoporosis. Thus, growth factors such as
BMP-7 could offer a promising opportunity to introduce
osteoinductive properties in a resorbable hydrogel-based
material. As evaluated in the present study, the murine
retrograde injection model of the femoral bone appears
to be feasible for further in vivo studies on the thera-
peutic potential on growth factor loaded BDI-hydrogel
for preventing secondary osteoporotic femoral fractures
in the future. Additional studies will be necessary to
reach translation to clinical routine.
Additional files
Additional file 1: Table S1. Normalized data on trabecular and cortical
bone relative to the characteristics of therapy (treatment and duration)




Fig. 4 Immunohistochemical detection of BMP-7 in mineralized
femora obtained 4 weeks (left column) and 12 weeks (right column)
after intramedullary application of BMP-7 loaded BDI-hydrogel, plain
BDI-hydrogel, or saline (SHAM) (Scale bar, 100 μm)
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and localization of the VOI (mean±SD, n=6 each treatment group).
(PDF 34 kb)
Additional file 2: Toluidine blue-labelled BDI-hydrogel injected into
cadaveric femora shows homogenous dispersion of the material in the
cavity. (TIFF 2150 kb)
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